← All Adial Pharmaceuticals, INC filings

Adial Pharmaceuticals, INC DEF 14A proxy statements

Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.

NASDAQ
ADIL
Adial Pharmaceuticals, INC
DEF: Adial Pharma Seeks Shareholder Nod for Warrant Exercise
Adial Pharmaceuticals, Inc. will hold a special meeting on February 26, 2026, to seek stockholder approval for the issuance of up to 13,823,512 shares of common stock related to Series F warrant exercises.
NASDAQ
ADIL
Adial Pharmaceuticals, INC
DEFR14A: Adial Pharmaceuticals Seeks Shareholder Approval for Reverse Stock Split, Capital Raises, and Equity Plan Expansion Amidst Nasdaq Compliance Challenges
Adial Pharmaceuticals, Inc. is calling its 2025 Annual Meeting to vote on critical proposals including a reverse stock split to regain Nasdaq compliance, approval for significant warrant exercises to raise capital, and an increase in authorized shares for future flexibility.
NASDAQ
ADIL
Adial Pharmaceuticals, INC
DEF: Adial Pharmaceuticals Seeks Shareholder Approval for Reverse Stock Split and Warrant Exercise Amid Nasdaq Compliance Challenges
Adial Pharmaceuticals, Inc. is calling its 2025 Annual Meeting of Stockholders to vote on critical proposals including a reverse stock split to regain Nasdaq compliance and the issuance of shares from recent warrant exercises, aiming to secure vital funding despite significant financial losses and internal control weaknesses.
NASDAQ
ADIL
Adial Pharmaceuticals, INC
DEF 14A: Adial Pharmaceuticals Sets Date for 2024 Annual Stockholders Meeting, Proposes Equity Incentive Plan Amendment
Adial Pharmaceuticals will hold its 2024 Annual Meeting of Stockholders on November 12, 2024, to vote on director elections, auditor ratification, an equity incentive plan amendment, and executive compensation.